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Diseases of follicular occlusion syndrome [hidradenitis suppu-
rativa (HS), acne conglobata (AC), dissecting cellulitis of the
scalp (DCS) and pilonidal sinus disease (PSD)] occur in associ-
ation with one another. This observation has been established
for more than 60 years through the work of Pillsbery et al.1
and explained through follicular occlusion as the inciting
event leading to follicular rupture, dermal inflammation and
(occasionally) fibrosis and fistulae formation. With the current
paradigm shift in HS as a disease where follicular occlusion
may be secondary rather than a primary phenomenon,2 the
role of inflammation as a primary driver in other follicular
occlusion disorders merits consideration.
In this issue, Benhadou et al.3 provide the initial epidemio-
logical evidence required to reconsider PSD as within the
spectrum of inflammatory dermatoses related to HS. Interest-
ingly, the pathogenesis of PSD mirrors previous pathological
paradigms in HS. Both diseases were considered infectious
and the result of perspiration and poor hygiene, both con-
sider occlusion to be major contributing factors and epidemi-
ological associations with smoking, obesity and metabolic
syndrome are well established.4 The most tantalizing possibil-
ity is that PSD may be an extension of the latent classifica-
tion (LC)2/LC3/gluteal continuum of male-predominant/
smoking-predominant HS.5 This would open up the potential
for nonsurgical therapies for those with complex, recurrent
disease.
The clinical and histological diagnosis of PSD/HS, as Ben-
hadou et al. have discussed, is inherently prone to diagnostic
and confirmation bias.3 The same intergluteal lesion, in the
hands of a surgeon or a dermatologist may be called PSD or
HS, respectively. A general surgeon excising a PSD where
extensive genital and inguinal lesions exist may be more
inclined to document the lesion as HS, whereas axillary lesions
may go unnoticed. A pathological diagnosis may be swayed
by clinical notes indicating a history of HS, or a pathologists’
knowledge of HS, given that no reproducible pathological cri-
teria are widely used. Such biases, inherent in a retrospective
observational study may explain some of the associations in
clinical diagnosis, such as the negative association of axillary
lesions with intergluteal HS.
The next stage is comparative histology,4 lesional inflamma-
tory mediators and prospective clinical studies in order to vali-
date the work of Benhadou et al.3 Such work should be
encouraged not just in PSD, but also in DCS and AC, where
the possibility of common inflammatory and mechanistic
pathways may lead to increasing nonsurgical treatment options
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Acne is one of the most common skin conditions affecting all
age groups, especially adolescents and young adults.1 The
transition into adulthood is a crucial period of development
including many changes and challenges, such as professional
progress, making and strengthening relationships and forming
one’s personal identity.2 Having visible acne impedes these
developmental tasks and, in the absence of a cure, affected
people must learn to live with their skin condition. Effective
treatments are therefore essential. In order to measure efficacy
of different treatments, well-developed and validated patient-
reported outcome measures should be available and capture
improvements from the patient’s perspective.3 Being an
important outcome of acne treatments, appearance should be
measured in every clinical trial. What is more important for
an affected patient, especially for adolescents and young
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adults, than how their skin, acne and acne scars look and
improve? Because appearance is in the eye of the beholder, a
self-report is needed to capture this concept. There are some
acne-specific measures available, but they often overlook this
subjective concept. In this issue of the BJD, Klassen et al. dared
to develop a new instrument filling this gap, the ACNE-Q.4
Addressing the concept appearance comprehensively, this mea-
sure is novel. An important criterion to ensure good quality of
the development of a measure is a patient-oriented approach.
Patients as well as different healthcare providers were involved
in the whole development process. Three top-level domains
with several major and minor themes emerged. Feedback of
clinical experts was obtained and cognitive interviews with
affected patients were conducted to assess content validity of
the scales according to the COSMIN criteria.5 Modern psycho-
metric analyses using the Rasch Measurement Theory were
performed to identify items with poor fit and different mea-
surement properties of the ACNE-Q, such as structural validity,
internal consistency, test–retest reliability and construct valid-
ity, were assessed. The study is limited to the North American
population. However, a large sample size (n = 256) recruited
from two countries and different settings, i.e. hospital and
community dermatology clinics, was involved in the valida-
tion study. Although the ACNE-Q is quite long, with 73 items
in seven scales, it is a comprehensive and promising measure
that can be used in clinical practice and research to measure
appearance and appearance-related distress and symptoms.
This study lays the ground for future studies on the validation
and feasibility of the ACNE-Q.
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Cellular senescence, the transition of many different mitotic cell
types to a permanently nondividing state accompanied by a pro-
found change in phenotype, is now recognized as a primary
cause of ageing and ill health in mammals. Multiple lines of evi-
dence have led to this conclusion, including the observations that
normal human fibroblasts have a limited capacity to divide
in vitro, that this capacity is dependent on the age and health status
of donors, that diseases such as Werner syndrome and Hutchin-
son–Gilford progeria syndrome combine premature fibroblast
senescence in vitro with a host of clinical changes resembling age-
ing in vivo and the demonstration that experimental deletion of
senescent cells in transgenic mice extends lifespan and improves
health.1,2 The entry of human fibroblasts into senescence triggers
a phenotypic shift marked by reduced production of collagen and
overproduction of collagenase coupled with the release of a range
of antiproliferative and proinflammatory cytokines collectively
termed the senescence-associated secretory phenotype (SASP).1
Exposure to SASP components induces senescence in a paracrine
fashion, consistent with the evolutionary role of senescence as a
tumour-suppression mechanism.
In light of these findings there is growing clinical interest
in the development of senolytics, compounds that can selec-
tively destroy senescent cells, with the first open-label clinical
trial conducted earlier this year.3 However, an alternative
route to clinical benefit is the reversion of senescent cells to a
growth-competent phenotype through the development of
antidegenerative compounds. Perhaps the first demonstration
of the utility of this approach was the work of Latorre and
colleagues who showed that treatment of multiple strains of
senescent human fibroblasts with resveralogues allowed the
cells to escape senescence and reinitiate division.4 This
occurred via a resetting of the pattern of RNA splicing factors,
probably via the extracellular signal-regulated kinase (ERK)
and AKT pathways.5
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